# Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

> **NCT03332095** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 55 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Doravirine (DOR)
- **DRUG:** Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)
- **DRUG:** Antiretroviral (ARV) medications

## Key facts

- **NCT ID:** NCT03332095
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-02
- **Primary completion:** 2020-08-19
- **Final completion:** 2022-05-25
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332095, "Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03332095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*